CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 86 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $4,936,363 | -4.6% | 120,723 | -1.4% | 0.01% | 0.0% |
| Q1 2024 | $5,175,412 | +63.4% | 122,437 | +63.9% | 0.01% | +75.0% |
| Q4 2023 | $3,166,856 | +110.0% | 74,690 | +8.1% | 0.00% | +100.0% |
| Q3 2023 | $1,508,213 | -37.3% | 69,089 | -8.8% | 0.00% | -33.3% |
| Q2 2023 | $2,407,266 | +29.4% | 75,724 | -0.7% | 0.00% | 0.0% |
| Q1 2023 | $1,859,640 | -23.5% | 76,246 | -1.1% | 0.00% | -25.0% |
| Q4 2022 | $2,431,198 | +18.7% | 77,083 | +6.3% | 0.00% | +33.3% |
| Q3 2022 | $2,049,000 | +5.5% | 72,499 | -1.4% | 0.00% | 0.0% |
| Q2 2022 | $1,943,000 | +0.3% | 73,498 | +32.8% | 0.00% | 0.0% |
| Q1 2022 | $1,938,000 | +1.3% | 55,347 | -6.2% | 0.00% | +50.0% |
| Q4 2021 | $1,913,000 | +14.8% | 58,999 | +4.5% | 0.00% | 0.0% |
| Q3 2021 | $1,666,000 | +33.7% | 56,480 | +16.1% | 0.00% | 0.0% |
| Q2 2021 | $1,246,000 | – | 48,634 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 65,679,781 | $2,685,646,245 | 57.02% |
| Twin Securities, Inc. | 416,657 | $17,037,105 | 13.40% |
| Sand Grove Capital Management LLP | 919,023 | $37,578,850 | 10.99% |
| Perceptive Advisors | 10,794,876 | $441,402,480 | 10.63% |
| P SCHOENFELD ASSET MANAGEMENT LP | 796,440 | $32,566,432 | 7.87% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,353,694 | $96,242,547 | 4.60% |
| Avoro Capital Advisors LLC | 7,539,547 | $308,292,077 | 4.11% |
| Melqart Asset Management (UK) Ltd | 1,099,229 | $44,947,474 | 3.72% |
| Paradigm Biocapital Advisors LP | 2,330,508 | $95,294,472 | 3.65% |
| WATER ISLAND CAPITAL LLC | 766,933 | $31,360 | 3.33% |